Related Experiment Video

Updated: Nov 3, 2025

Separating Bacteria by Capsule Amount Using a Discontinuous Density Gradient
05:52

Separating Bacteria by Capsule Amount Using a Discontinuous Density Gradient

Published on: January 7, 2019

14.4K

Carbapenem-Resistant Klebsiella pneumoniae Associated with COVID-19

Irina Magdalena Dumitru1,2,3, Mirela Dumitrascu1, Nicoleta Dorina Vlad1,3

  • 1Clinical Infectious Diseases Hospital, 100 Ferdinand Str, 900709 Constanta, Romania.

Antibiotics (Basel, Switzerland)
|June 2, 2021
PubMed

Insights

Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections pose a significant threat in hospitals, especially in COVID-19 patients. New strains of CRKP led to high mortality rates, even with advanced treatments.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Antimicrobial Resistance

Background:

  • Carbapenem-resistant Enterobacteriaceae (CRE) infections are a growing global health concern.
  • Carbapenem-resistant Klebsiella pneumoniae (CRKP) is the most prevalent CRE species in healthcare settings.
  • CRKP infections are linked to high morbidity and mortality, particularly in vulnerable patients.

Observation:

  • Nine intensive care unit (ICU) patients with severe COVID-19 developed invasive infections.
  • These infections were caused by carbapenemase-producing Klebsiella pneumoniae (CP-Kp) strains (KPC and OXA-48), previously unidentified in the hospital.
  • Five patients succumbed to the infections despite treatment with ceftazidime/avibactam.

Findings:

  • The emergence of novel CP-Kp strains in critically ill COVID-19 patients presents a severe clinical challenge.
  • Coinfections with CRKP significantly worsen the prognosis for COVID-19 patients, especially the elderly.
  • High mortality rates underscore the limited therapeutic options against these resistant pathogens.

Implications:

  • There is an urgent need for enhanced surveillance and infection control measures for CRKP in ICUs.
  • Rigorous antibiotic stewardship programs are crucial to combat the spread of carbapenem-resistant organisms.
  • Further research into novel therapeutic strategies against CP-Kp is essential for improving patient outcomes.

Keywords:
COVID-19KPCcarbapenem-resistant Klebsiella pneumoniaecarbapenemase

More Related Videos

Author Spotlight: Advancing Rapid Detection of Respiratory Pathogens Using Microfluidic Chip06:11

Author Spotlight: Advancing Rapid Detection of Respiratory Pathogens Using Microfluidic Chip

Published on: March 29, 2024

2.1K
Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia08:05

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Published on: December 19, 2020

14.4K

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
454
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
1.4K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
548
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
538
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
98
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
435